- SEXUAL DYSFUNCTION IN POSTMENOPAUSAL WOMEN(Enrollment Closed)
- ENDOMETRIOSIS (Enrollment Closed)
- ENDOMETRIOSIS(Enrollment Closed)
- ORAL CONTRACEPTION (Enrollment Closed)
- ORAL CONTRACEPTION (Enrollment Closed)
- ORAL CONTRACEPTION(Enrollment Closed)
- GENITAL HERPES(Enrollment Closed)
- HPV TESTING (Enrollment Closed)
- HPV TESTING (Enrollment Closed)
- OVERACTIVE BLADDER
- BREAST PAIN (Enrollment Closed)
- ANEMIA (Enrollment Closed)
- ANEMIA
- INTRAUTERINE DEVICE (IUD) (Enrollment Closed)
- OBESITY (Enrollment Closed)
- VASOMOTOR SYMPTOMS (HOT FLASHES) ASSOCIATED WITH MENOPAUSE
(Enrollment Closed)
- BACTERIAL VAGINOSIS/VULVAVAGINAL CANDIDIASIS (BV/VVC)
- OVERACTIVE BLADDER
- CONTRACEPTION (TRANSDERMAL PATCH) enrollment begins Feb 2009
- ORAL CONTRACEPTION
SEXUAL DYSFUNCTION
Purpose
The primary objective is to estimate the incidence of endometrial hyperplasia associated with the testosterone transdermal patch therapy in naturally postmenopausal women with hypoactive sexual desire disorder (HSDD) who are not using concomitant estrogen/progestin therapy.
Study Population
Generally healthy women must:
- be naturally postmenopausal (at least 1 year) and 45 to 70 years of age. Women must not have had a hysterectomy. Removal of one ovary is allowed.
- be using a stable continuous combined daily regimen of systemic estrogen and progestin or not be using systemic estrogen and progestin therapy for at least 12 weeks prior to Visit 1.
Back to top
ENDOMETRIOSIS
Purpose
The primary objective of this study is to assess the effects of two dose regimens on bone mineral density following 24 weeks of treatment to reduce pain associated with laproscopically proven endometriosis.
Study Population
Menstruating females between the ages of 18 and 49 with moderate-to-severe nonmenstrual pelvic pain
Back to top
ENDOMETRIOSIS
Purpose
The primary objective of this study is to assess the safety and efficacy of a vaginal formulation of danazol administered in 2 different regiments to subjects with laproscopically proven endometriosis.
Study Population
Menstruating females no less than 18 and no more than 50 years of age with moderate-to-severe nonmenstrual pelvic pain
Back to top
ORAL CONTRACEPTION
Purpose
The primary objective of this study is to evaluate and compare bleeding patterns between three different dose extended cycle (91-day) oral contraceptive regimens.
Study Population
Females aged 18-45 years old that are not at risk for pregnancy and have an understanding and comprehension of the English language
Back to top
ORAL CONTRACEPTION
Purpose
The objectives of this study are to assess the efficacy of an oral contraception in the prevention of pregnancy and the incidence of intracyclic bleeding (IB).
Study Population
Females aged 18-45 years old that are not at risk for pregnancy and have an understanding and comprehension of the English language
Back to top
ORAL CONTRACEPTION
Purpose
The primary objective of this study is to evaluate the efficacy and safety of an oral contraceptive in a flexible variation of an extended regimen administered for one year.
Study Population
Healthy females 18 to 35 years of age (smokers with a maximum age of 30 years) that are not at risk for pregnancy and have an understanding and comprehension of the English language
Back to top
GENITAL HERPES
Purpose
The primary objective is to compare the efficacy of single-day treatment with an already approved herpes medication to that of a placebo in patient-initiated episodic treatment of recurrent genital herpes
Study population
The study is conducted to evaluate treatment effects and safety of single-day treatment of recurrent genital herpes in a Black population, as an insufficient number of Black patients was included in the initial study. The patients must be equal or greater than 18 years of age and not immunocompromised.
Study medications and labs will be free. Financial compensation for time and travel will be provided.
Back to top
HPV TESTING
Purpose
The primary objective of this study is to establish the clinical sensitivity and specificity for the detection of cervical intraepithelial grade 3 (CIN3) or cancer by testing for certain types of HPV in DNA purified from liquid-based cervical cytology samples.
Study population
A sufficient number of women greater than or equal to 30 years of age undergoing routine cervical cancer screening (pap smear).
Study medications and labs will be free. Financial compensation for time and travel will be provided.
Back to top
HPV TESTING
Purpose
The primary objective of this study is to evaluate the efficacy of a gel medication over a range of concentrations and dosing regimens when compared to placebo based on regression (clearance) of high-risk (HR) cervical HPV infection in women with low-grade squamous intraepithelial lesions (LSIL) or atypical squamous cells of undetermined significance (ASC-US). The current design of this study is based upon the results from 3 completed studies; 2 phase I studies and a phase II study.
Study population
Females that:
- are positive for HR genotypes of HPV and have a liquid-based pap cytology interpreted as LSIL or ASC-US.
- have no evidence of high-grade disease or glandular abnormalities.
- have a clinically normal immune system
- are not suffering from clinically significant medical illnesses or sexually transmitted diseases.
Back to top
OVERACTIVE BLADDER
Purpose
The primary objective is to evaluate the effects of a medication for overactive bladder symptoms in comparison to placebo as a study calibrator.
Study Population
Females no less than 18 and no more than 70 years of age with diagnosis of overactive bladder with symptoms of urgency with incontinence and frequency, which may be associated with nocturia, but without bladder pain.
Study medications and labs will be free. Financial compensation for time and travel will be provided.
Please fill out our questionnaire Click here(Internet Explorer only)
Back to top
BREAST PAIN
Purpose
The primary objective is the evaluation of efficacy of a medication by comparing the proportion of patients in the treatment and placebo groups that experience a clinically meaningful reduction in breast pain and tenderness as measured over 6 months.
Study Population
Otherwise healthy, euthyroid, premenopausal women with moderate and/or severe periodic breast pain and tenderness for at least six days per cycle and an established history of symptomatic fibrocystic breast disease for whom malignancy has been excluded and who are unresponsive to conservative treatment such as local heat, non-prescription analgesics and properly fitted garments.
Back to top
ANEMIA
Purpose
The primary objective of this study is to demonstrate the superiority of the GI safety profile of Repliva 21/7 over that of ferrous sulfate in subjects with iron deficiency anemia.
Study population
Eligible subjects are women from 18 to 60 years age with iron deficiency anemia for whom iron supplementation is appropriate, but who are otherwise in generally good health.
Back to top
ANEMIA
Purpose
The primary objective of this study is to further evaluate the safety of the maximum administered dose of an investigational IV iron (ferric carboxymaltose) compared to Standard Medical Care in the treatment of Iron Deficiency Anemia (IDA) in Heavy Uterine Bleeding and Postpartum Patients.
Study population
Female subjects that qualify as having:
- iron deficiency anemia and
- postpartum or
- history of Heavy Uterine Bleeding, defined as one of the following:
- inability to control flow with tampons alone
- use of more than 12 pads per period or 4 tampons per day within the past 6 months
- passage of clots, especially if they are larger than a nickel size in diameter or if they persist after the first day
- period duration exceeding 7 days
Study medications and labs will be free. Financial compensation for time and travel will be provided.
Please fill out our questionnaire Click here(Internet Explorer only)
Back to top
INTRAUTERINE DEVICE (IUD)
Purpose
The primary objective of this study is to assess the safety, efficacy and pharmacokinetics of a new intrauterine contraceptive system administered for 3 years.
Study Population
Healthy 18 to 35 year-old nulliparous or parous females in need of contraception that are not at risk for pregnancy and have an understanding and comprehension of the English language
Study medications and labs will be free. Financial compensation for time and travel will be provided.
Back to top
OBESITY
Purpose
The primary objective of this dose-ranging study is to evaluate the effects of an obesity medication as compared with placebo on percent change in body weight from baseline through Week 12.
Study Population
Men and women 18 to 65 years of age, including those possessing controlled hypertension and/or treated or untreated dyslipidemia.
Study medications and labs will be free. Financial compensation for time and travel will be provided.
Back to top
HOT FLASHES
Purpose
The primary objective of this study is to determine the lowest effective dose of an oral medication for the relief of moderate to severe vasomotor symptoms in postmenopausal women.
Study Population
Postmenopausal women ? 40 years of age with spontaneous amenorrhea or postsurgical bilateral oophorectomy with or without hysterectomy.
Study medications and labs will be free. Financial compensation for time and travel will be provided.
Back to top
BV/VVC Infections
Purpose
The objective of this study is to demonstrate that a vaginal cream is superior in efficacy and comparable in safety to ClindesseO Vaginal Cream and Gynazole-1O Vaginal Cream in the treatment of mixed BV/VVC infections.
Study Population
Nonpregnant females 18 years of age or older with mixed BV/VVC infections
Study medications and labs will be free. Financial compensation for time and travel will be provided.
Please fill out our questionnaire Click here(Internet Explorer only)
Back to top
OVERACTIVE BLADDER
Purpose
The purpose of this study is to evaluate the efficacy and safety of and Oxybutynin Vaginal Ring for overactive bladder symptoms in comparison to placebo as a study calibrator.
Study Population
Females 18 years of age or older, ambulatory, with a history and presentation consistent with pure or predominantly urge incontinence for greater than or equal to 6 months.
Study medications and labs will be free. Financial compensation for time and travel will be provided.
Please fill out our questionnaire Click here(Internet Explorer only)
Back to top
CONTRACEPTION
Purpose
The primary objective of this study is to evaluate the contraceptive efficacy of the transdermal contraceptive patch.
Study Population
Females aged 18-35 with a history of regular cyclic menstrual periods.
Study medications and labs will be free. Financial compensation for time and travel will be provided.
Please fill out our questionnaire Click here(Internet Explorer only)
Back to top
ORAL CONTRACEPTION
Purpose
Healthy females 18 to 50 years of age (smokers with a maximum age of 30 years) that are suffering from pelvic pain or headache while using a 21-day oral contraceptive that contains LNG (Levonorgeterel) or NGM (Norgestimate) and are willing to switch their current medication to the study medication.
Study Population
Females aged 18-35 with a history of regular cyclic menstrual periods.
Study medications and labs will be free. Financial compensation for time and travel will be provided.
Study medications and labs will be free. Financial compensation for time and travel will be provided.
Please fill out our questionnaire Click here(Internet Explorer only)
Back to top
